Development of cobalt(3,4-diarylsalen) complexes as tumor therapeutics

[1,6-Bis(2-hydroxyphenyl)-3,4-diaryl-2,5-diazahexa-1,5-dienelcobalt(II) complexes (cobalt(3,4-diarylsalen)) with 2-, 3-, or 4-OCH3/OH substituents in the 3,4-standing aryl rings were synthesized and tested for antitumor activity in vitro on the MCF-7, MDA-MB 231, and LNCaP/FGC cell lines. The cytotoxicity depended on both the configuration of the diene ligand and the kind of substituents in the 3,4-standing aromatic rings. d,1-7 (2-OCH3), d,1-8 (3-OCH3) and d,1-9 (4-OCH3) were equipotent to cisplatin, while the respective hydroxy-substituted complexes (d,1-10 (2-OH), d,1-11 (3-OH), and d,1-12 (2-OH)) as well as all of the meso-configured compounds (m-7 to m-12) did not influence the cell growth. Interestingly, a high catalytic potency and a rapid and high accumulation in MCF-7 cells (15- to 25-fold compared to the cell culture medium (5 muM)) were demonstrated for m-7 (2-OCH3), m-8 (3-OCH3) and m-9 (4-OCH3). Therefore, a mode of action based on a cobalt-catalyzed oxidative damage of the DNA is not very likely.